In addition, a trivalent CAR-T cell combines three CAR molecules that could target HER2, IL13Rα2, and EphA2, respectively, and kill tumor cells expressing single or multiple antigens, expanding the therapeutic range [375]. Here, ERBB2 is linked to neoplasm.